Abuja, Nigeria — Nigeria has become the first African nation to receive mpox vaccines, marking a significant milestone in the global fight against the disease. The country has been gifted 10,000 doses of the Jynneos (MVA) vaccine by the United States, aimed at combating the spread of mpox within its borders.
The ceremonial handover took place in Abuja on Tuesday, August 27, just a week after the World Health Organization (WHO) declared mpox a global health emergency. Dr. Muyi Aina, Executive Director and CEO of the National Primary Healthcare Development Agency, underscored the importance of the occasion. “Today’s handover ceremony symbolizes more than a transfer of vaccines; it exemplifies the power of international cooperation in addressing both global and local health challenges,” Aina stated.
The vaccine donation comes at a time of constrained global supply, with only about 200,000 doses available worldwide. “We’re aware that this vaccine is not exactly in surplus supply,” Dr. Aina acknowledged. “I believe we are receiving 10,000 of the available doses.”
The Jynneos (MVA) vaccine, which has been donated by the U.S. government, is designed to prevent mpox infection, particularly for individuals at high risk of contracting the disease. This preventive measure is crucial for managing the spread of mpox, which has seen a resurgence in recent times.
The U.S. government’s decision to first deliver the vaccine to Nigeria was influenced by the country’s well-structured vaccination plan. “The Nigerian government has put together a comprehensive vaccination plan,” explained the U.S. envoy to Nigeria. “This plan outlines how to use these vaccines effectively and maximize their impact. That’s why Nigeria was selected to receive this initial batch. We will continue to collaborate with Nigeria to combat the spread of mpox.”
The Democratic Republic of Congo, the epicenter of the global mpox outbreak, is also set to receive support. The U.S. has pledged to donate 50,000 doses to the country as part of a broader effort to control the outbreak.
According to the WHO, most individuals with mpox recover within 2-4 weeks. The primary goal in treating the disease is to manage symptoms such as rashes and pain, while also preventing complications. The arrival of these vaccines in Nigeria is expected to bolster efforts to contain and ultimately reduce the incidence of mpox across the country.
The vaccine distribution marks a crucial step in Nigeria’s response to the mpox outbreak, embodying the spirit of international solidarity and cooperation in addressing pressing global health issues.
Discussion about this post